Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world evaluation of Inclisiran vs traditional lipid-lowering in high ASCVD risk patients
ChiCTR2500106915Phase 4Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Jul 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of inclisiran in atherosclerotic disease, hypercholesterolemia and dyslipidemia (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoints: Reduction in LDL-C levels and Rate of achieving LDL-C targets. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
inclisiran
03
Conditions
atherosclerotic diseasehypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on ChiCTR2500106915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106915.